Bluejay Diagnostics Valuation Multiples

Bluejay Diagnostics is valued at $4M as of October 2026. In the last fiscal year, Bluejay Diagnostics EBITDA was ($7M).

Bluejay Diagnostics Overview

About Bluejay Diagnostics

Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay’s first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from ‘sample-to-result’ to help medical professionals make earlier and better triage/treatment decisions.


Founded

2015

HQ

United States

Employees

7

Financials (Last FY)

Revenue: -
EBITDA: ($7M)

Market Cap

$4M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Bluejay Diagnostics Financials

Bluejay Diagnostics reported last fiscal year revenue of - and negative EBITDA of ($7M).

In the same fiscal year, Bluejay Diagnostics generated ($2M) in gross profit, ($7M) in EBITDA losses, and had net loss of ($7M).


Bluejay Diagnostics P&L

In the most recent fiscal year, Bluejay Diagnostics reported revenue of - and EBITDA of ($7M).

Bluejay Diagnostics is unprofitable as of last fiscal year, with gross margin of -, EBITDA margin of -, and net margin of -.

See analyst estimates for Bluejay Diagnostics
LTMLast FY202320242025202620272028
Gross Profit-($2M)---
EBITDA-($7M)($9M)($7M)($7M)
Net Profit($9M)($7M)($10M)($8M)($7M)
Net Debt-($5M)---

Financial data powered by Morningstar, Inc.

Bluejay Diagnostics Stock Performance

Bluejay Diagnostics has current market cap of $4M.

Market Cap Evolution


Bluejay Diagnostics' stock price is $0.84.

Bluejay Diagnostics share price decreased by 2.7% in the last 30 days.

Bluejay Diagnostics has an EPS (earnings per share) of $-1.53.

See more trading valuation data for Bluejay Diagnostics
Market CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$4M-0.7%-2.7%--$-1.53

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Bluejay Diagnostics Valuation Multiples

Bluejay Diagnostics Financial Valuation Multiples

As of October 4, 2026, Bluejay Diagnostics has market cap of $4M.

Bluejay Diagnostics has a P/E ratio of (0.4x).

LTMLast FY202320242025202620272028
P/E(0.4x)(0.5x)(0.4x)(0.5x)(0.5x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Bluejay Diagnostics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Bluejay Diagnostics Margins & Growth Rates

Bluejay Diagnostics grew net profit by 7% in the last fiscal year.

See estimated margins and future growth rates for Bluejay Diagnostics

Bluejay Diagnostics Growth Rates

FY+1/FY23/2424/2526/2727/2828/29
Gross Profit Growth(353%)--
EBITDA Growth-(27%)(1%)
EBIT Growth17%(30%)(3%)
Net Profit Growth7%(22%)(11%)
FCF Growth-(10%)(23%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Bluejay Diagnostics Operational KPIs

Bluejay Diagnostics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.0M for the same period.

Access forward-looking KPIs for Bluejay Diagnostics
Last FY202620272028
Revenue per Employee$0.0M
Opex per Employee$1.0M

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Bluejay Diagnostics Competitors

Bluejay Diagnostics competitors include Subgen AI, Monivent, NRGene, INVO Fertility, Sonendo, Spineway, Massmedica, PharmaCyte Biotech, ScandiDos and Virax Biolabs Group.

Most Bluejay Diagnostics public comparables operate across Diagnostics & Genomics, Medical Devices, BioTech and DeepTech.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Subgen AI$20M($1M)----
Monivent$142K($780K)28.0x-(5.1x)-
NRGene$3M($975K)0.2x-(0.6x)-
INVO Fertility$7M($4M)0.7x0.7x(1.3x)-
Sonendo$32M($27M)0.1x0.1x(0.2x)-
Spineway$14M($1M)0.1x0.1x(1.5x)(6.0x)
Massmedica$8M$446K0.7x-12.5x-
PharmaCyte Biotech-($20M)----

This data is available for Pro users. Sign up to see all Bluejay Diagnostics competitors and their valuation data.

Start Free Trial

Bluejay Diagnostics VC Funding History

Before going public, Bluejay Diagnostics raised $3M in total equity funding, across 2 rounds.


Bluejay Diagnostics Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Jun-21SeedCentrecourt Asset Management$1M--
Apr-17Seed-$2M--

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Bluejay Diagnostics

When was Bluejay Diagnostics founded?Bluejay Diagnostics was founded in 2015.
Where is Bluejay Diagnostics headquartered?Bluejay Diagnostics is headquartered in United States.
How many employees does Bluejay Diagnostics have?As of today, Bluejay Diagnostics has over 7 employees.
Is Bluejay Diagnostics publicly listed?Yes, Bluejay Diagnostics is a public company listed on Nasdaq.
What is the stock symbol of Bluejay Diagnostics?Bluejay Diagnostics trades under BJDX ticker.
When did Bluejay Diagnostics go public?Bluejay Diagnostics went public in 2021.
Who are competitors of Bluejay Diagnostics?Bluejay Diagnostics main competitors include Subgen AI, Monivent, NRGene, INVO Fertility, Sonendo, Spineway, Massmedica, PharmaCyte Biotech, ScandiDos, Virax Biolabs Group.
What is the current market cap of Bluejay Diagnostics?Bluejay Diagnostics' current market cap is $4M.
Is Bluejay Diagnostics profitable?No, Bluejay Diagnostics is not profitable.
What is the current net income of Bluejay Diagnostics?Bluejay Diagnostics' last 12 months net income is ($9M).
How many companies Bluejay Diagnostics has acquired to date?Bluejay Diagnostics hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Bluejay Diagnostics has invested to date?Bluejay Diagnostics hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Bluejay Diagnostics

Lists including Bluejay Diagnostics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial